PERAMPanEL STUDY FOR INFANTS WITH EPILEPSY

Perampanel is already approved by FDA for treatment of partial-onset seizures in patients with epilepsy aged 4 years and older, and as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.

WHO: Children (1 month to less than 24 months) with epilepsy, taking at least 1 (maximum 3) seizure medications

WHAT: Looking at the safety and tolerability of the study drug Perampanel when added to a participant’s existing anti-seizure medications

WHERE: Multiple centers in the United States and one in Latvia

HOW: Participants who are eligible will take Perampanel by mouth, and visit with a healthcare provider every 2 to 12 weeks during the study for a maximum of 58 weeks

For more information, visit https://www.epilepsy.com/eisai